Relapsed/refractory patients

CARTITUDE-1 trial: Is JNJ-4528 safe and efficacious for patients with RRMM?

L: English

The Multiple Myeloma Hub is pleased to present a series of expert interviews from the 61st American Society of Hematology (ASH) meeting in Orlando, US. In this video, Deepu Madduri, Icahn School of Medicine at Mount Sinai, New York, US, answers the question: Based on the CARTITUDE-1 trial, is JNJ-4528 safe and efficacious for patients with relapsed/refractory multiple myeloma?

JNJ-4528 is a second-generation chimeric antigen T-cell receptor containing two BCMA-targeting single-domain antibodies. Based on the CARTITUDE-1 trial, JNJ-4528 delivers early and deep responses with a manageable safety profile in patients with refractory multiple myeloma.